《Nature,9月9日,The coding capacity of SARS-CoV-2》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-09-16
  • The coding capacity of SARS-CoV-2

    Yaara Finkel, Orel Mizrahi, Aharon Nachshon, Shira Weingarten-Gabbay, David Morgenstern, Yfat Yahalom-Ronen, Hadas Tamir, Hagit Achdout, Dana Stein, Ofir Israeli, Adi Beth-Din, Sharon Melamed, Shay Weiss, Tomer Israely, Nir Paran, Michal Schwartz & Noam Stern-Ginossar

    Nature (2020)

    Abstract

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing Coronavirus disease 19 (COVID-19) pandemic1. In order to understand SARS-CoV-2 pathogenicity and antigenic potential, and to develop therapeutic tools, it is essential to portray the full repertoire of its expressed proteins. The SARS-CoV-2 coding capacity map is currently based on computational predictions and relies on homology to other coronaviruses. Since coronaviruses differ in their protein array, especially in the variety of accessory proteins, it is crucial to characterize the specific collection of SARS-CoV-2 proteins in an unbiased and open-ended manner. Using a suite of ribosome profiling techniques2–4, we present a high-resolution map of the SARS-CoV-2 coding regions, allowing us to accurately quantify the expression of canonical viral open reading frames (ORFs) and to identify 23 unannotated viral ORFs. These ORFs include upstream ORFs (uORFs) that are likely playing a regulatory role, several in-frame internal ORFs lying within existing ORFs, resulting in N-terminally truncated products, as well as internal out-of-frame ORFs, which generate novel polypeptides. We further show that viral mRNAs are not translated more efficiently than host mRNAs; rather, virus translation dominates host translation due to high levels of viral transcripts. Our work provides a rich resource, which will form the basis of future functional studies.

  • 原文来源:https://www.nature.com/articles/s41586-020-2739-1
相关报告
  • 《9月9日_以色列科学家分析SARS-CoV-2的编码能力》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-09-16
    • 9月9日,魏兹曼科学研究所和以色列生物研究所的科研人员在Nature期刊上发表题为“The coding capacity of SARS-CoV-2”的文章。 文章指出,为了了解SARS-CoV-2的致病性和抗原潜力,并开发治疗工具,必须描绘其蛋白表达的全部组成。SARS-CoV-2编码能力图目前基于计算预测,并依赖于与其他冠状病毒的同源性。由于冠状病毒的蛋白质阵列不同,尤其是辅助蛋白的种类不同,因此以一种无偏见和开放的方式表征SARS-CoV-2蛋白的特定集合至关重要。研究人员使用一套核糖体分析技术,展示了SARS-CoV-2编码区的高分辨率图,准确地量化了规范性病毒开放阅读框(ORF)的表达,并识别了23个未注释的病毒ORFs。这些ORFs包括可能发挥调节作用的上游ORFs(uORFs),存在于现有ORFs内的多个框架内部ORFs以及框架外部ORFs。研究人员表示,病毒mRNA的翻译效率并不比宿主mRNA高,由于病毒转录物水平较高,病毒翻译主导了宿主翻译。 原文链接:https://www.nature.com/articles/s41586-020-2739-1
  • 《Nature,6月9日,Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-10
    • Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Brandi N. Williamson, Friederike Feldmann, Benjamin Schwarz, Kimberly Meade-White, Danielle P. Porter, Jonathan Schulz, Neeltje van Doremalen, Ian Leighton, Claude Kwe Yinda, Lizzette Pérez-Pérez, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Greg Saturday, Catharine M. Bosio, Sarah Anzick, Kent Barbian, Tomas Cihlar, Craig Martens, Dana P. Scott, Vincent J. Munster & Emmie de Wit Nature (2020) Abstract Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection9. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.